Literature DB >> 24426325

Chronic lymphocytic leukemia: inception to cure: are we there?

Deepesh P Lad1, Pankaj Malhotra1, Subhash Varma1.   

Abstract

There have been remarkable advances in our understanding of the biology and therapeutics of chronic lymphocytic leukemia. B cell receptor signaling and micro-environment in CLL biology have been the most modern areas of research. In CLL therapeutics, we have come a long way from alkylating agents to chemo-immunotherapy. Despite this there remain significant lacunae in the disease biology that has hindered our quest to achieve the ultimate in CLL: Cure. This review aims to summarize the past, present and future in the biology and treatment of CLL.

Entities:  

Keywords:  Biology; Chronic lymphocytic leukemia; Review; Treatment

Year:  2012        PMID： 24426325      PMCID： PMC3572254          DOI： 10.1007/s12288-012-0192-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  63 in total

Review 1.  T-cell function in chronic lymphocytic leukaemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Semin Cancer Biol       Date:  2010-10-27       Impact factor: 15.707

2.  Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jan Dürig; Laimonas Griskevicius; Stephan Stilgenbauer; Jirí Mayer; Lukás Smolej; Georg Hess; Rasa Griniute; Francisco J Hernandez-Ilizaliturri; Swaminathan Padmanabhan; Michele Gorczyca; Chai-Ni Chang; Geoffrey Chan; Ira Gupta; Tina G Nielsen; Charlotte A Russell
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

3.  Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages.

Authors:  Massimo Gentile; Giovanna Cutrona; Antonino Neri; Stefano Molica; Manlio Ferrarini; Fortunato Morabito
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

4.  Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.

Authors:  Wolfgang Kern; Ulrike Bacher; Claudia Haferlach; Frank Dicker; Tamara Alpermann; Susanne Schnittger; Torsten Haferlach
Journal:  Br J Haematol       Date:  2012-01-09       Impact factor: 6.998

5.  Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Bercedis L Peterson; John G Gribben; Vicki A Morrison; Kanti R Rai; Richard A Larson; John C Byrd
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.

Authors:  S Molica; A Alberti
Journal:  Cancer       Date:  1987-12-01       Impact factor: 6.860

8.  Chronic lymphocytic leukemia: "Cinderella" is becoming a star.

Authors:  Federico Caligaris-Cappio
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

9.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Mohamed L Sorror; Barry E Storer; Brenda M Sandmaier; Michael Maris; Judith Shizuru; Richard Maziarz; Edward Agura; Thomas R Chauncey; Michael A Pulsipher; Peter A McSweeney; James C Wade; Benedetto Bruno; Amelia Langston; Jerald Radich; Dietger Niederwieser; Karl G Blume; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

Review 10.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486
View more
  1 in total

1.  In vitro and in vivo assessment of biocompatibility of AZ31 alloy as biliary stents: a preclinical approach.

Authors:  Yong Song; Gaoping Qin; Lixue Du; Haitian Hu; Yong Han
Journal:  Arch Med Sci       Date:  2020-01-31       Impact factor: 3.318
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.